During the corresponding time, Plus Therapeutics Inc saw a revenue deteriorated by -70.43 % year on year, sequentially revenue fell by -60.02 %. While revenue at the Plus Therapeutics Inc 's corporate clients
Plus Therapeutics Inc's Comment on Sales, Marketing and Customers
The company serves customers who bill federal programs such as Medicare and Medicaid for products. Its market segments include clinical laboratories, which may be subject to enforcement under the federal civil False Claims Act related to claims submitted for government payment. The company also works with manufacturers of drugs, devices, biological, and medical supplies eligible for payment under Medicare, Medicaid, or the Children’s Health Insurance Program. Additionally, it serves physicians, advanced practice professionals, and teaching hospitals that receive payments or transfers of value reported under the Physician Payments Sunshine Act. Furthermore, manufacturers and wholesale distributors of drug, device, and biological products must comply with state laws regarding registration and product distribution.
At the recently concluded Society for Neuro-Oncology (SNO) Annual Conference in 2024, Plus Therapeutics presented compelling interim data from its ReSPECT-LM Phase 1 trial, examining the efficacy of Rhenium-186 nanoLiposome (186RNL) in patients suffering from leptomeningeal metastases. This groundbreaking research has the potential to reshape the therapeutic landscape for a notoriously difficult-to-treat condition that often accompanies various malignancies, including breast, lung, and melanoma cancers.Leptomeningeal metastases, characterized by the spread of cancer cells to the membranes surrounding the brain and spinal cord, pose significant challenges in clinical management. Traditional systemic therapies...
Revolutionizing Cancer Treatment: Plus Therapeutics Groundbreaking Advances in CNSide Assays and ReSPECT Clinical Trials for CNS Metastases Plus Therapeutics is pushing the frontiers of oncology with its latest research and clinical trial data, offering hope and innovative solutions to patients grappling with challenging metastatic conditions. At two prestigious conferences, the 2024 Congress of Neurological Surgeons Annual Meeting and the SNO/ASCO CNS Metastases Conference, the company unveiled significant findings that underscore the potential of their novel diagnostic and treatment methodologies. CNSide Cerebrospinal Fluid Assay: A Breakthrough in Diagnosing Leptomeningeal Metastases Leptomeningeal metas...
Unlocking New Horizons in Neuro-Oncology: Plus Therapeutics Pioneering Advances in Leptomeningeal Metastases and Glioblastoma MultiformePlus Therapeutics is making notable strides in the realm of neuro-oncology, showcasing their ground-breaking work across two pivotal areas: leptomeningeal metastases and glioblastoma multiforme (GBM). The company has recently shared significant updates on their innovative CNSide Cerebrospinal Fluid Assay and the ReSPECT-GBM clinical trial, each reflecting their dedication to advancing treatment options and improving patient outcomes. CNSide Assay: A Multi-Institutional Effort In a promising development, Plus Therapeutics is slated to present its multi-institutional experie...
In a significant development for the biopharmaceutical sector, Plus Therapeutics Inc. (NASDAQ: PSTV) has announced a strategic manufacturing partnership with SpectronRx, focused on advancing their radiotherapeutic production capabilities. This collaboration is set to enhance Plus Therapeutics position in the competitive oncology market, particularly as they work towards the commercialization of their innovative therapies.The partnership aims to leverage SpectronRx’s expertise in radiopharmaceutical manufacturing, which is crucial for the development of targeted therapies that address various forms of cancer. By collaborating with a company specialized in this niche, Plus Therapeutics hopes to streamline i...
In the luminescent halls of progress, where the realms of medicine and fortitude converge, a bastion of hope doth arise in the form of Plus Therapeutics Inc. This month, amidst the cacophony of economic fluctuations that hath beset the marketplace, the enterprising company hath drawn the attention of the esteemed members of the medical fraternity, particularly at the illustrious Congress of Neurological Surgeons Annual Meeting, a paramount gathering of minds devoted to the alleviation of afflictions that besiege the brain.As the curtains were drawn upon the War against Glioblastoma Multiforme (GBM), Plus Therapeutics hath publicly showcased its interim findings from the ReSPECT-GBM Phase 2 trial a beacon of ...
Plus Therapeutics, an oncology-focused pharmaceutical company, recently provided updates on two major fronts its Leptomeningeal Metastases acquisition and topline data from The Foresee (186Re) trial. Leptomeningeal metastases (LM), a severe complication of cancer, results from the spread of malignant cells to the leptomeninges, the surfaces encapsulating the brain and spinal cord. Plus Therapeutics has embarked on the acquisition of a clinical development program specifically targeting this condition. This step aligns with the company s mission to constantly innovate and provide potentially life-changing treatments for cancer patients, focusing particularly on rare and heavily burdened cancers.Additionally, ...
In a groundbreaking collaboration, Plus Therapeutics has joined forces with K2bio to develop innovative tests for the analysis of cerebrospinal fluid (CSF) tumor cells and molecular biomarkers. This partnership aims to explore novel CSF cancer testing modalities, offering hope for improved diagnostics and personalized treatment options. With an initial testing panel set to be available in the first quarter of 2024, this collaboration holds immense potential for ReSPECT-LM patients and marks a significant milestone in the fight against brain cancer. The importance of early detection and accurate diagnosis in cancer cannot be overstated. However, current CSF testing methods in the clinical settin...
Plus Therapeutics Inc’s Comment on Sales, Marketing and Customers
The company serves customers who bill federal programs such as Medicare and Medicaid for products. Its market segments include clinical laboratories, which may be subject to enforcement under the federal civil False Claims Act related to claims submitted for government payment. The company also works with manufacturers of drugs, devices, biological, and medical supplies eligible for payment under Medicare, Medicaid, or the Children’s Health Insurance Program. Additionally, it serves physicians, advanced practice professionals, and teaching hospitals that receive payments or transfers of value reported under the Physician Payments Sunshine Act. Furthermore, manufacturers and wholesale distributors of drug, device, and biological products must comply with state laws regarding registration and product distribution.
Sources:
Plus Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Plus Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Plus Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
340.63 %